# US 2009/0269366 A1 · T cell epitope peptides of 6b11 ovarian cancer anti-idiotypic antibody > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2009/0269366 A1 - Document ID: US20090269366A1 - Status: Published application - Kind: A1 - Application number: 12/303,244 - Filed: 2007-06-04 - Published: 2009-10-29 - Earliest claimed: 2006-06-02 - Assignees: Peking University People;s Hospital - Inventors: Heng Cui; Wei Li; Xiaohong Chang; Jie Feng; Hongyan Cheng; Huifang Guo; Yexia Cheng - Web page: https://patentgrep.com/patent/US20090269366A1 ## CPC - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61P 35/00: Antineoplastic agents - A61K 40/42: Cancer antigens - A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2} - A61K 2039/892: {Reproductive system [uterus, ovaries, cervix, testes]} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention provides two T-cell epitode peptides of anti-idiotype antibody 6B11 of ovarian cancer, the sequences of which are shown in SEQ ID NO:3 or 6. The present invention also provides the use of such T-cell epitope peptides in the manufacture of vaccines against ovarian cancer and in the treatment and prevention of ovarian cancer. The T-cell epitope peptides of the present invention could specifically kill ovarian cancer cells which are OC166-9 positive, and could find a wide use in the treatment and prevention of ovarian cancer. ## Claims ### Claim 1 An epitope peptide, wherein the amino acid sequence of the epitope peptide: (1) is set forth in SEQ ID NO:3 or 6; or (2) has a substitution, deletion or addition of one or several amino acids compared with the amino acid sequence of SEQ ID NO:3 or 6, and has substantially the same biological activity as that of SEQ ID NO:3 or 6. ### Claim 2 (depends on 1) The epitope peptide according to claim 1, wherein the amino acid sequence of the epitope peptide is set forth in SEQ ID NO:3. ### Claim 3 (depends on 2) The epitope peptide according to claim 2, wherein the epitope peptide is a Th epitope peptide. ### Claim 4 (depends on 1) The epitope peptide according to claim 1, wherein the amino acid sequence of the epitope peptide is set forth in SEQ ID NO:6. ### Claim 5 (depends on 4) The epitope peptide according to claim 4, wherein the epitope peptide is a CTL epitope peptide. ### Claim 6 (depends on 1) The epitope peptide according to claim 1, wherein the epitope peptide is derived from anti-idiotype antibody 6B11 of ovarian cancer. ### Claim 7 (depends on 1) The epitope peptide according to claim 1, wherein the eptitope peptide induces a cellular immune response against ovarian cancer. ### Claim 8 (depends on 1) A nucleic acid molecule encoding the epitope peptide according to claim 1. ### Claim 9 (depends on 8) A vector comprising the nucleic acid molecule according to claim 8. ### Claim 10 (depends on 1) A pharmaceutical composition for the treatment or prevention of ovarian cancer, comprising the epitope peptide according to claim 1 as active ingredient and a pharmaceutically acceptable carrier. ### Claim 11 A pharmaceutical composition for the treatment or prevention of ovarian cancer, comprising both the epitope peptide set forth in SEQ ID NO:3 and the epitope peptide set forth in SEQ ID NO:6. ### Claim 12 (depends on 1) A vaccine against ovarian cancer, comprising the epitope peptide according to claim 1 and a heat shock protein. ### Claim 13 (depends on 12) The vaccine against ovarian cancer according to claim 12, wherein said epitope peptide and said heat shock protein are fused to form the fusion protein. ### Claim 14 (depends on 13) The vaccine against ovarian cancer according to claim 13, wherein said epitope peptide and said heat shock protein are linked by a linker peptide to form the fusion protein. ### Claim 15 (depends on 12) The vaccine against ovarian cancer according to claim 12, wherein said epitope peptide and said heat shock protein bind reversibly. ### Claim 16 (depends on 12) The vaccine against ovarian cancer according to claim 12, wherein said heat shock protein is a human or murine HSP70 or gp96. ### Claim 17 (depends on 1) A method for the treatment or prevention of ovarian cancer, comprising administering to a subject a therapeutically or prophylactically effective amount of the epitope peptide according to claim 1. ### Claim 18 A method for the treatment or prevention of ovarian cancer, comprising administering the epitope peptide set forth in SEQ ID NO:3 and the epitope peptide set forth in SEQ ID NO:6 simultaneously, sequentially or separately. ### Claim 19 (depends on 12) A method for the prevention of ovarian cancer, comprising administering to a subject an effective amount of the vaccine against ovarian cancer according to claim 12. ### Claim 20 (canceled) ### Claim 21 (canceled) ### Claim 22 (depends on 1) An assay kit, comprising the epitope peptide according to claim 1. ### Claim 23 (depends on 10) A method for the treatment or prevention of ovarian cancer, comprising administering to a subject a therapeutically or prophylactically effective amount of the pharmaceutical composition according to claim 10.